HealthCapVC's profile picture. HealthCap is a family of venture capital funds investing globally in life sciences and is one of the largest life science specialized VC's in Europe.

HealthCap

@HealthCapVC

HealthCap is a family of venture capital funds investing globally in life sciences and is one of the largest life science specialized VC's in Europe.

Dear friends of @HealthCapVC. We will suspend our Twitter. Communications will be through our website healthcap.eu and Linked-In linkedin.com/company/health…. Please follow us there.


Priothera - Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy healthcap.eu/ycmp


Oncopeptides’ Pepaxti has been granted marketing authorization in the UK healthcap.eu/eyn9


Oncopeptides announces the market potential for Pepaxti in Europe healthcap.eu/7c2w


Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21 healthcap.eu/k36j


Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership healthcap.eu/0om5


Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen healthcap.eu/t21w


BONESUPPORT’s CERAMENT®G used in first U.S. patient cases healthcap.eu/ceec


Targovax - The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info healthcap.eu/lxyf


Vicore selects new ATRAG as next Drug Candidate healthcap.eu/tui7


Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study healthcap.eu/ykv5


InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth healthcap.eu/rgch


Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market healthcap.eu/4m0u


Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA healthcap.eu/vdpo


Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC healthcap.eu/wo57


Vicore announces that C21 promotes vascular function in humans healthcap.eu/0nsc


Sesen Bio and Carisma Therapeutics Announce Merger Agreement healthcap.eu/dinm


Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published healthcap.eu/ik81


Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease healthcap.eu/gj3l


Vicore provides an update on the ATTRACT-3 COVID-19 trial healthcap.eu/gtzr


Loading...

Something went wrong.


Something went wrong.